Seres Therapeutics(US:MCRB) Globenewswire·2025-10-30 11:00Core Insights - Seres Therapeutics, Inc. will host a conference call on November 5, 2025, at 8:30 a.m. ET to discuss Q3 2025 financial results and business updates [1][2] Company Overview - Seres Therapeutics is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics [3] - The company developed VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024 [3] - Seres is developing SER-155, which has received Breakthrough Therapy designation for reducing bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing infection risk and graft-versus-host disease in the same patient group [3] - SER-155 demonstrated a significant reduction in bloodstream infections and related complications compared to placebo in a Phase 1b clinical study [3] - The company plans to evaluate SER-155 and other cultivated live biotherapeutic candidates in various medically vulnerable populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, and solid organ transplant recipients [3]